Product Pathways - Tyrosine Kinase / Adaptors
Human EGF Neutralizing (D8A1) Rabbit mAb #12157
PhosphoSitePlus® protein, site, and accession data: EGF
| Applications | Reactivity | Isotype |
|---|---|---|
| N | H | Rabbit IgG |
Applications Key:
N=Neutralizing
Reactivity Key:
H=Human
Species cross-reactivity is determined by western blot. Species enclosed in parentheses are predicted to react based on 100% sequence homology.
Specificity / Sensitivity
Human EGF Neutralizing (D8A1) Rabbit mAb binds to human EGF and neutralizes its effects in an MCF 10A cell proliferation assay. This antibody does not cross-react with human betacellulin or human TGF-α.
Source / Purification
Monoclonal antibody is produced by immunizing animals with a recombinant human EGF protein.
Bioactivity
The ability of Human EGF Neutralizing (D8A1) Rabbit mAb to inhibit hEGF-induced MCF 10A cell proliferation was assessed. MCF 10A cells were treated with increasing concentrations of antibody in the presence of hEGF #8916 (2 ng/ml). After 24 hr, cells were labeled with BrdU for 4 hr and BrdU incorporation was determined using BrdU Cell Proliferation Assay Kit #6813.
Bioactivity
The proliferation of MCF 10A cells treated with increasing concentrations of hEGF #8916 was assessed. After 24 hr, cells were labeled with BrdU for 4 hr and BrdU incorporation was determined using BrdU Cell Proliferation Assay Kit #6813.
Description
Neutralizing antibodies can be used to inhibit normal biological function through their binding to biological molecules. These reagents can be used to determine the effects that a particular molecule has in biological systems. Human EGF Neutralizing (D8A1) Rabbit mAb has been shown to neutralize the EGF-induced proliferation of MCF 10A cells in vitro with an ND50 in the range of 200-700 ng/ml.
Endotoxin
<0.1 EU/µg of antibody
Formulation
Lyophilized from a 0.2 µm filtered solution in 10 mM HEPES with trehalose.
Background
EGF is produced by epithelial cells, fibroblasts, and many other cell types (1,2). Low molecular weight soluble EGF is generated through proteolysis of a larger ~130,000 kDa transmembrane precursor (1,2). Both soluble and membrane forms of EGF are active (2). EGF induces proliferation, differentiation, and survival of many cell types including tumor-derived cells (1-3). There are multiple members of the EGF family and multiple members of the HER/ErbB EGF receptor family. EGF binds to HER1/ErbB1 and induces homo- or heterodimerization with other HER/ErbB family members, resulting in signaling through the MAPK, PI3K/Akt, and Stat5 pathways (1). Research studies have implicated EGF, EGF family members, EGF receptors, and their signaling pathways in many cancers (1,2).
- Citri, A. and Yarden, Y. (2006) Nat Rev Mol Cell Biol 7, 505-16.
- Higashiyama, S. et al. (2008) Cancer Sci 99, 214-20.
- Xian, C.J. (2007) Endocr Rev 28, 284-96.
Application References
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
Companion Products
For Research Use Only. Not For Use In Diagnostic Procedures.
